Should You Buy Bio Path Holdings Inc (BPTH) Stock After it Is Higher By 2.94% in a Week?

Bio Path Holdings Inc (BPTH) stock has gained 2.94% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Bio Path Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BPTH!

See Full BPTH Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With BPTH Stock Today?

Bio Path Holdings Inc (BPTH) stock is trading at $0.70 as of 1:27 PM on Monday, Oct 23, an increase of $0.01, or 1.79% from the previous closing price of $0.69. The stock has traded between $0.63 and $0.74 so far today. Volume today is low. So far 967,909 shares have traded compared to average volume of 5,460,009 shares. To screen for more stocks like Bio Path Holdings Inc click here.

More About Bio Path Holdings Inc

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Click Here to get the full Stock Report for Bio Path Holdings Inc stock.